|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn972092250 |
| 003 |
OCoLC |
| 005 |
20231120112212.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170210s2017 enk ob 001 0 eng d |
| 010 |
|
|
|a 2017285243
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d EBLCP
|d OPELS
|d IDEBK
|d N$T
|d YDX
|d CNCGM
|d OTZ
|d OCLCQ
|d OCLCO
|d MERER
|d OCLCO
|d OCLCQ
|d OCLCO
|d D6H
|d DKU
|d OCLCO
|d OCLCQ
|d U3W
|d OCLCO
|d OCLCQ
|d OCLCO
|d AU@
|d OCLCO
|d CASUM
|d WYU
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d S2H
|d OCLCO
|d VT2
|d OCLCO
|d OCLCQ
|d SFB
|
| 066 |
|
|
|c (S
|
| 016 |
7 |
|
|a 101706618
|2 DNLM
|
| 019 |
|
|
|a 972425308
|a 972567983
|a 972802724
|a 973014318
|a 973082845
|a 973322858
|a 1004969179
|a 1066465665
|a 1235832812
|
| 020 |
|
|
|a 9780128026250
|q (electronic bk.)
|
| 020 |
|
|
|a 0128026251
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128024201
|q (print)
|
| 020 |
|
|
|z 0128024208
|
| 035 |
|
|
|a (OCoLC)972092250
|z (OCoLC)972425308
|z (OCoLC)972567983
|z (OCoLC)972802724
|z (OCoLC)973014318
|z (OCoLC)973082845
|z (OCoLC)973322858
|z (OCoLC)1004969179
|z (OCoLC)1066465665
|z (OCoLC)1235832812
|
| 050 |
|
4 |
|a RC280.B7
|
| 060 |
|
4 |
|a 2017 D-843
|
| 060 |
|
4 |
|a WL 358
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/48106
|2 23
|
| 245 |
0 |
0 |
|a Translational immunotherapy of brain tumors /
|c edited by John H. Sampson.
|
| 264 |
|
1 |
|a London, United Kingdom :
|b Academic Press, an imprint of Elsevier,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|6 880-01
|a Front Cover; TRANSLATIONALIMMUNOTHERAPY OFBRAIN TUMORS; TRANSLATIONALIMMUNOTHERAPYOF BRAINTUMORS; Copyright; Contents; List of Contributors; Introduction to Translational Immunotherapy for Brain Tumors; TRANSLATIONAL IMMUNOTHERAPY FOR BRAIN TUMORS SUMMARY; PRIMER ON MALIGNANT GLIOMAS; THE POTENTIAL OF CANCER IMMUNOTHERAPY; CHALLENGES OF BRAIN TUMOR IMMUNOTHERAPY; CHAPTER OVERVIEW; References; I -- IIMMUNOLOGICALFEATURES OF BRAINTUMORS; 1 -- An Introduction to Immunotherapy in the Treatment of Brain Tumors; INTRODUCTION; THE IMMUNE RESPONSE; IMMUNE TOLERANCE
|
| 505 |
8 |
|
|a UNIQUE ASPECTS OF THE CENTRAL NERVOUS SYSTEM IMMUNE RESPONSEThe Blood-Brain Barrier; The CNS Lymphatic System; Antigen Presentation in the CNS; CANCER IMMUNOTHERAPIES; References; 2 -- Immune Constitution of Patients With Brain Tumors; BACKGROUND AND DISCOVERY; CURRENT UNDERSTANDING: ANALYZING SYSTEMIC IMMUNE DYSFUNCTION; Lymphopenia; Lymphocyte Dysfunction; Regulatory T Cells; CURRENT UNDERSTANDING: ANALYZING THE TUMOR; Cytokine Dysregulation; Signal Transducer and Activator of Transcription-3; Indoleamine 2,3 Dioxygenase; CLINICAL OPPORTUNITIES
|
| 505 |
8 |
|
|a Countering T Cell Dysfunction: Immune Checkpoint BlockadeCountering Regulatory T Cells and Lymphopenia; Countering Cytokine Dysregulation; Countering Tumor STAT3 and IDO Expression; CONCLUSION; References; 3 -- The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression; BACKGROUND AND DISCOVERY; ORIGIN OF TREGS; FUNCTION OF TREGS; TREGS IN THE CANCER IMMUNITY CYCLE; TREGS AND GLIOMA; TRYPTOPHAN CATABOLISM IN IMMUNITY AND IN CANCER; IDO1, IDO2, AND TDO; THE AHR; MECHANISMS OF IMMUNE REGULATION BY THE IDO PATHWAY; THE IDO PATHWAY IN CANCER AND IN GLIOMA
|
| 505 |
8 |
|
|a TARGETING TREGS IN PRECLINICAL MODELTARGETING IDO IN PRECLINICAL MODELS; CLINICAL TRIAL DATA; CONCLUSION; References; 4 -- The Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors; BACKGROUND AND DISCOVERY OF THE MYELOID CELL; MDSCs in Mice; MDSCs in Humans; MDSC Activation, Proliferation, Migration, and Expansion; Suppressive Mechanisms Mediated by MDSCs; Suppression via Arg1 and iNOS; Suppression via Reactive Oxygen Species; Suppression via Peroxynitrite; Other Immunosuppressive Mechanisms; MDSCs in Glioma Development; PRECLINICAL DATA: TARGETING THE MDSC POPULATION
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed February 17, 2017).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Brain
|x Tumors
|x Immunotherapy.
|
| 650 |
1 |
2 |
|a Brain Neoplasms
|x therapy
|0 (DNLM)D001932Q000628
|
| 650 |
|
6 |
|a Cerveau
|0 (CaQQLa)201-0075615
|x Tumeurs
|0 (CaQQLa)201-0075615
|x Immunoth�erapie.
|0 (CaQQLa)201-0380098
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 700 |
1 |
|
|a Sampson, John H.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Translational immunotherapy of brain tumors.
|d London, United Kingdom : Academic Press, an imprint of Elsevier, 2017
|z 0128024208
|z 9780128024201
|w (OCoLC)959874904
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128024201
|z Texto completo
|
| 880 |
8 |
|
|6 505-01/(S
|a Chemokine and Cytokine ApproachesDifferentiation; IL-4Rα Targeting; Arginase 1; Fibrinogen-Like Protein 2 Targeting; M1 Polarization or M2 Blockade; CLINICAL APPROACHES TO TARGETING MDSCS; References; 5 -- Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy; INTRODUCTION; MUTATIONS AS IMMUNOTHERAPEUTIC TARGETS; ISOCITRATE DEHYDROGENASE 1 MUTATIONS IN GLIOMAS; IDH1 MUTATIONS AS AN IMMUNOTHERAPEUTIC TARGET; PRECLINICAL INVESTIGATIONS: IDH1-R132H PEPTIDE VACCINES; CLINICAL INVESTIGATIONS: IDH1-R132H PEPTIDE VACCINES
|
